BofA Securities stays Buy on Catalyst Pharma (CPRX) amid Angelini acquisition interest reports
Tweet Send to a Friend
BofA Securities analyst Jason M. Gerberry reiterated a Buy rating and $35.00 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX)The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
